Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine. Issue 13 (18th March 2022)

• Record Type: Journal Article
• Authors: Yamamoto, Shohei; Fukunaga, Ami; Tanaka, Akihito; Takeuchi, Junko S.; Inoue, Yosuke; Kimura, Moto; Maeda, Kenji; Ueda, Gohzoh; Mizoue, Tetsuya; Ujiie, Mugen; Sugiura, Wataru; Ohmagari, Norio
• Is Part Of: Vaccine. Volume 40:Issue 13(2022)
• Page Start: 1924
• Page End: 1927
• Publication Date: 2022-03-18
• Subjects: Reactogenicity -- Spike IgG titer -- SARS-CoV-2 -- Fever -- BNT162b2 vaccine; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2022.02.052
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: High vaccine reactogenicities may reflect stronger immune responses, but the epidemiological evidence for coronavirus disease 2019 (COVID-19) vaccines is sparse and inconsistent. We observed that a fever of ≥38℃ after two doses of the BNT162b2 vaccine was associated with higher severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike IgG titers.